Regulatory inspections can feel unpredictable, but most findings follow similar tendencies across FDA, EMA, and DCGI reviews. A strong FDA inspection-readiness mindset is not about preparing for one visit; it is about building a system
Read MoreQ1. What is a pharmacovigilance (PV) system? A PV system is a combined set of processes, people, and technology that a company uses to collect, assess, and act on information about the safety of its
Read More
Most companies don’t think about pharmacovigilance until they’re forced to. A product gets approved, the first adverse event report lands in someone’s inbox, and suddenly, there’s a scramble to figure out: who owns the process,
Read MoreAccelerated approval pathways are designed to bring important therapies to patients sooner, especially in serious or life-threatening diseases with unmet medical needs. For a regulatory service provider, the key value is helping sponsors choose the
Read More
The electronic Common Technical Document has been the global standard for pharma dossier management for over two decades. Most organisations built their workflows around eCTD 3.2.2 and moved on. In 2026, three developments are forcing
Read More
If you have ever sat across a regulatory team trying to prepare simultaneous dossiers for the US FDA, EMA, and CDSCO, you already know the feeling. It is not just about assembling data. It is
Read More
Regulatory affairs has never exactly been a slow moving field. But 2026 feels different. Agencies that spent years cautiously watching AI from a distance are now actively deploying it. Real world evidence once a nice
Read MoreGiven the abundance of connected devices, cloud-linked systems, software-driven platforms, and their ability to pose direct risks to patient safety, data integrity, and product reliability, Cybersecurity has now become more than a compliance issue. From
Read MoreIndia’s pharmaceutical market continues to expand, and with the growth comes greater responsibility for drug safety oversight. The Central Drugs Standard Control Organization (CDSCO) plays a central role in shaping the country’s pharmacovigilance framework. Key
Read MoreIndia’s pharmaceutical sector is evolving from high-volume output to strategic global importance. The domestic market, currently USD 50–60 billion, is projected to reach USD 130 billion by 2030. With FY2026 growth forecasts of 7%–11%, India
Read More